Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs ACAM 529 (Primary)
- Indications Herpes simplex virus type 2 infections
- Focus Adverse reactions
- 08 Oct 2017 Results presented at the IDWeek 2017.
- 07 Mar 2017 Status changed from active, no longer recruiting to completed.
- 02 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History